Pipeline
Debiopharm International’s projects cover all molecule type proteins, peptides, small molecules
Oncology
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ Debio 0123
Oncology – Wee1 kinase inhibitor
Wee1 kinase inhibitor
_ Debio 0123 +lunresertib
Advanced solid tumors – Wee1 & PKMYT1 inhibitor
Wee1 & PKMYT1 inhibitor
Repare
_ Debio 4126
Acromegaly – Synthetic Somatostatin analogue
Synthetic Somatostatin analogue
Repare: Repare Therapeutics
ITM: ITM Isotope Technology Munich SE
Merck: Merck KGaA
Infectious decease
Program
Indication
Mode of Action
Discovery
Preclinical
Phase I
Phase II
Phase III
_ afabicin (Debio 1450)
Bone & joint infections – FabI inhibitor
FabI inhibitor
ODD/FT/QIDP
_ afabicin (Debio 1450)
ABSSSI – FabI inhibitor
FabI inhibitor
FT/QIDP
_ Debio 1455
Inflammatory Bowel Disease – Microbiome remodeling
Microbiome remodeling
ODD: Orphan Drug Designation
FT: Fast-Track
QIDP: Qualified Infectious Disease Product
CARB-X: CARB-X grant
-
Want to know more about our pipeline?Discover the full pipeline
Discover our 18 studies from discovery to phase III in oncology and bacterial infections
-
Want to partner with us?Contact us
Do you have a promising oncology or antibacterial compound? Or are you interested in commercializing one of our programs?